ImmunityBio Slapped With FDA Refusal To File Letter For Expanded Use Of Its Bladder Cancer Drug

Why did Warren Buffett step down from Berkshire Hathaway? How will Trump's 100% foreign film tariffs impact Hollywood? What caused Tesla's stock decline in Europe? Why are states suing Trump over wind energy policies? How is the Fed likely to act on interest rates this week? What are the effects of OPEC+ increasing oil production? How will Apple’s App Store fee ruling appeal affect developers? Why is Skechers being taken private amid trade tensions? What is the impact of student loan collections resuming?

ImmunityBio Slapped With FDA Refusal To File Letter For Expanded Use Of Its Bladder Cancer Drug

benzinga.com/general/biotech/25/05/45193720/immunitybio-slapped-with-fda-refusal-to-file-letter-for-expanded-use-of-its-bladder-cancer-drug

ImmunityBio, Inc. (NASDAQ:IBRX) on Monday received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) for the supplemental biologics license application (sBLA) for use of ANKTIVA plus Bacillus Calmette-Guerin (BCG) in BCG-unresponsive non-muscle invasive…

This story appeared on benzinga.com, 2025-05-05 13:21:28.